共 50 条
- [21] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMANDGASTROENTEROLOGY, 2024, 166 (05) : S238 - S238Schreiber, StefanPanaccione, RemoParkes, Gareth C.Peyrin-Biroulet, LaurentFerrante, MarcHisamatsu, TadakazuSiegmund, BrittaKalabic, JasminaLevine, PhillipNeimark, EzequielWallace, KoriChen, SuCheng, LingDuan, W. RachelArmuzzi, AlessandroBiedermann, LucLoftus, Edward V.Melmed, GilLouis, Edouard
- [22] Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study ResultsINFLAMMATORY BOWEL DISEASES, 2023, : 1421 - 1430Panes, JulianLoftus, Edward, VHiggins, Peter D. R.Lindsay, James O.Zhou, WenYao, XuanIlo, DapoPhillips, CharlesTran, JacindaSanchez Gonzalez, YuriVermeire, Severine
- [23] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH studyJOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022Vermeire, S.Danese, S.Zhou, W.Pangan, A.Greenbloom, S.D'Haens, G.Panes, J.Juillerat, P.Lindsay, J. O.Loftus, E. V., Jr.Sandborn, W. J.Reinisch, W.Gonzalez, Y. SanchezHuang, B.Xie, W.Liu, J.Weinreich, M. A.Panaccione, R.
- [24] Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S357Vermeire, SeverineDanese, SilvioZhou, WenPangan, AileenGreenbloom, SusanD'Haens, GeertPanes, JulianJuillerat, PascalLindsay, JamesLoftus, Edward V.Sandborn, WilliamReinisch, WalterSanchez-Gonzalez, YuriHuang, BidanXian, WangangLiu, JianzhongWeinreich, MichaelPanaccione, Remo
- [25] Impact of Inflammatory Burden on Efficacy of Upadacitinib Maintenance Therapy in Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S515 - S516Feagan, Brian G.Colombel, Jean-FredericTorres, JoanaFujii, ToshimitsuZhou, WenYao, XuanSanchez-Gonzalez, YuriIlo, DapoRoblin, Xavier
- [26] Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitisJOURNAL OF CROHNS & COLITIS, 2023, 17 : I333 - I334Blumenstein, I.Xuan, S.Panaccione, R.Baert, F.Barreiro-de Acosta, M.Ye, B. D.Klaff, J.Vladea, R.Levy, G.Holweg, C. T. J.Gonzalez, Y. SanchezDubinsky, M. C.
- [27] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND StudyJOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12Louis, E.Panaccione, R.Parkes, G.Peyrin-Biroulet, L.Ferrante, M.Hisamatsu, T.Siegmund, B.Kalabic, J.Levine, P.Neimark, E.Wallace, K.Chen, S.Cheng, L.Duan, W. R.Armuzzi, A.Biederman, L.Loftus, E.Melmed, G.Schreiber, S.
- [28] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISGUT, 2017, 66 : A121 - A122Panes, J.Rubin, D. T.Vermeire, S.Lindsay, J. O.Sands, B. E.Su, C.Friedman, G.Zhang, H.Kayhan, C.Manuchehri, A.Healey, P.
- [29] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISGASTROENTEROLOGY, 2017, 152 (05) : S601 - S602Panes, JulianRubin, David T.Vermeire, SeverineLindsay, James O.Sands, Bruce E.Su, ChinyuFriedman, GaryZhang, HaiyingKayhan, CemManuchehri, AlirezaHealey, Paul J.
- [30] Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitisJOURNAL OF CROHNS & COLITIS, 2017, 11 : S315 - S317Panes, J.Rubin, D. T.Vermeire, S.Lindsay, J. O.Sands, B. E.